Hans Lilja
Titel
Adjungerad professor
Organisation
+12126396982
+19176286565
Hans [dot] Lilja [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
författare
- 2013
- 2012
- A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index.
- Evaluation of Multiple Risk-Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men
- Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function
- Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
- Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations.
- Microfluidic, Label-Free Enrichment of Prostate Cancer Cells in Blood Based on Acoustophoresis.
- Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.
- PSA is Dead, Long Live PSA
- Porous silicon antibody microarrays for quantitative analysis: Measurement of free and total PSA in clinical plasma samples.
- Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review
- Prostate-Cancer Mortality at 11 Years of Follow-up
- Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
- Screening for Prostate Cancer: Early Detection or Overdetection?
- Targeting Free Prostate-Specific Antigen for In Vivo Imaging of Prostate Cancer Using a Monoclonal Antibody Specific for Unique Epitopes Accessible on Free Prostate-Specific Antigen Alone.
- 2011
- A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening
- Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples
- Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(145) or Lys(146) from fPSA without internal cleavages at Lys(145) or Lys(146)
- Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
- Percentage of Free Prostate-specific Antigen: Implications in Modern Extended Scheme Prostate Biopsy EDITORIAL COMMENT
- Prediction of Significant Prostate Cancer Diagnosed 20 to 30 Years Later With a Single Measure of Prostate-Specific Antigen at or Before Age 50
- Prostate-specific Antigen/Solvent Interaction Analysis: A Preliminary Evaluation of a New Assay Concept for Detecting Prostate Cancer Using Urinary Samples EDITORIAL COMMENT
- Three genes expressing Kunitz domains in the epididymis are related to genes of WFDC-type protease inhibitors and semen coagulum proteins in spite of lacking similarity between their protein products
- Tumor markers in prostate cancer I: Blood-based markers
- 2010
- A Common Prostate Cancer Risk Variant 5 ' of Microseminoprotein-beta (MSMB) Is a Strong Predictor of Circulating beta-Microseminoprotein (MSP) Levels in Multiple Populations
- A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
- A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
- Association Between Glomerular Filtration Rate, Free, Total, and Percent Free Prostate-specific Antigen EDITORIAL COMMENT
- Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer.
- Characterization of PSA in clinical samples by mass spectrometry
- Characterization of PSA in clinical samples by mass spectrometry
- Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
- Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening.
- Identification of prostate specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms
- Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
- Mass spectrometric strategy for clearcut identification of prostate specific antigen in clinical Samples
- Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
- Polymorphisms at the Microseminoprotein-beta Locus Associated with Physiologic Variation in beta-Microseminoprotein and Prostate-Specific Antigen Levels
- Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
- Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication.
- Susceptibility Loci Associated with Prostate Cancer Progression and Mortality
- miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions.
- miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
- 2009
- Acoustic Whole Blood Plasmapheresis Chip for Prostate Specific Antigen Microarray Diagnostics.
- Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
- Association of Reported Prostate Cancer Risk Alleles With PSA Levels Among Men Without a Diagnosis of Prostate Cancer
- Increase in percent free prostate-specific antigen in men with chronic kidney disease.
- Multiplex approach for identification of PSA variants in clinical samples
- Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
- Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
- Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort
- Risk of Dying From Prostate Cancer in Men Randomized to Screening Differences Between Attendees and Nonattendees
- Screening and Prostate-Cancer Mortality in a Randomized European Study
- THE CONTINUING ROLE OF PROSTATE-SPECIFIC ANTIGEN AS A MARKER FOR LOCALIZED PROSTATE CANCER: 'DO NOT THROW THE BABY OUT WITH THE BATH WATER'
- THE P-MARK BIOBANK: A EUROPEAN MULTICENTER BIOREPOSITORY FOR PROSTATE CANCER RESEARCH
- Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands
- 2008
- Alteration of prostate specific antigen (PSA) in blood linked to cancer
- Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males
- ENSAM: Europium Nanoparticles for Signal Enhancement of Antibody Microarrays on Nanoporous Silicon.
- Editorial Comments.
- Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
- Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
- Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
- The role of SPINK1 in ETS rearrangement-negative prostate cancers
- Total prostate specific antigen stability confirmed after long-term storage of serum at -80C - Comment
- 2007
- A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
- Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy
- Can PSA velocity predict risk of death in men with prostate cancer?
- Circulating biomarkers for prostate cancer
- Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
- Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer
- Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy
- Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
- Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer
- Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence
- Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood
- PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section
- PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section
- Prostate cancer early detection. Clinical practice guidelines in oncology
- Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - Results from a prospective, population-based randomized controlled trial
- Reverse-Phase versus Sandwich Antibody Microarray, Technical Comparison from a Clinical Perspective.
- Reverse-phase versus sandwich antibody microarray, technical comparison from a clinical perspective
- 2006
- Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition
- Differential exoprotease activities confer tumor-specific serum peptidome patterns
- Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum
- High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry
- Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
- Intact Free Prostate-Specific Antigen and Free and Total Human Glandular Kallikrein 2. Elimination of Assay Interference by Enzymatic Digestion of Antibodies to F(ab')(2) Fragments.
- Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug
- Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C.
- Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
- 2005
- Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
- Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue
- Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.
- Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade
- Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues
- Individualized screening interval for prostate cancer based on prostate-specific antigen level - Results of a prospective, randomized, population-based study
- Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project
- Macro/Nano-Structured Silicon as Solid Support for Antibody Arrays: Surface Design, Reproducibility, and Assay Characteristics Enabling Discovery of Kallikrein Gene Products for Prostate Disease Diagnostics
- Testosterone as a predictor of pathological stage in clinically localized prostate cancer
- The evolution of a genetic locus encoding small serine proteinase inhibitors.
- Translational crossroads for biomarkers
- beta-Microseminoprotein binds CRISP-3 in human seminal plasma
- 2004
- An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6
- Androgen receptor CAG repeat length correlates with semen PSA levels in adolescence.
- Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio
- Development of sensitive immunoassays for free and total human glandular kallikrein 2
- Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
- Integrated selective enrichment target - a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases
- Isoformen des freien prostataspezifischen Antigens
- Lead time associated with screening for prostate cancer
- Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer
- Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
- Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma
- Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer
- Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
- The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin.
- The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable
- 2003
- A frequent allele codes for a truncated variant of semenogelin I, the major protein component of human semen coagulum
- Biology of prostate-specific antigen.
- Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection
- Expression and immunolocalisation of neutral endopeptidase in prostate cancer
- Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues
- Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening
- Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)
- Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen
- Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
- Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells InVitro or prostate cancer xenografts in vivo
- Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer
- Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA Committee
- Quantitative PSA RT-PCR for preoperative staging of prostate cancer
- Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation.
- Standardization of Two Immunoassays for Human Glandular Kallikrein 2.
- Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
- The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer
- Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
- 2002
- A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein.
- Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
- Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen
- Exogenous protein kinases A and C, but not endogenous prostasome-associated protein kinase, phosphorylate semenogelins I and II from human semen
- Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay
- Prediction of tumor heterogeneity in localized prostate cancer
- Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step
- Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease
- Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer
- 2001
- A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor
- Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing
- Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146
- Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes
- Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
- Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing
- Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer
- Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues
- Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients
- The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease
- Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers
- Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level
- 2000
- Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater
- Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
- Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer
- Sensitive and specific immunodetection of human glandular kallikrein 2 in serum
- Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues
- Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden
- 1999
- Characterization of epitope structure for 53 monoclonal antibodies against prostate-specific antigen
- Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL
- Early Diagnosis and Staging.
- Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids
- Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy
- Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen
- The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer
- The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects
- 1998
- Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling
- Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum
- 1997
- 1996
- 1995
- 1994
- 1993
- 1991
- 1989
